Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 22,209 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: dutogliptin, sitagliptin; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more

Conditions: Risk Behavior, Risk Reduction, Emotion Regulation
Interventions: Tablet TRAC Emotion Regulation Intervention; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 12 Years to 14 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: COVID-19
Interventions: Merimepodib, Matching Placebo, Remdesivir; Drug
Lead sponsor: ViralClear Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 10
States / cities: Phoenix, Arizona • Fort Lauderdale, Florida • Jacksonville, Florida + 6 more

Conditions: Gastroenteritis
Interventions: HIL-214, Placebo; Biological
Lead sponsor: HilleVax; Industry
Eligibility: 5 Months to 5 Months
Enrollment: 3,084 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tuberculosis
Interventions: Moxifloxacin, PA-824, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Tuberculosis
Interventions: PNU-100480, Placebo, Linezolid; Drug
Lead sponsor: Sequella, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: Neuromuscular electrical stimulation; Device
Lead sponsor: University of Vermont; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Alzheimer Disease
Interventions: NPT088, Placebo; Drug
Lead sponsor: Proclara Biosciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 23
States / cities: Costa Mesa, California • Fullerton, California • Long Beach, California + 20 more

Conditions: Pain
Interventions: 2% lidocaine gel, placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Inflammatory Bowel Diseases, Crohn's Disease
Interventions: Placebo, MORF-057; Drug
Lead sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 25
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more

Conditions: Tinnitus
Interventions: Tele-PTM, Wait List Control; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Endometriosis, Ovarian Hyperstimulation
Interventions: Placebo oral tablet, Letrozole; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Bocidelpar, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 8 Years to 16 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Sacramento, California • Kansas City, Kansas • Baltimore, Maryland + 2 more

Conditions: Phantom Limb Pain
Interventions: Perineural infusion [continuous peripheral nerve block(s)]; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more

Conditions: Hypertriglyceridemia, Cardiovascular Disease
Interventions: Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 89
States / cities: Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more

Conditions: Osteoarthritis, Osteo Arthritis Knee
Interventions: Colchicine 0.8 mg or 0.6 mg orally once daily, Placebo oral capsule; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Coronary Syndromes
Interventions: Clopidogrel (SR25990), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3,491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Sjogren's Syndrome
Interventions: Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 34
States / cities: Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions: CRD-740, Placebo; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 17
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 13 more

Conditions: Head and Neck Cancer
Interventions: NKTR-214, anti-PD-1 therapy, Palliative Radiation; Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide; Radiation · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 324
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more

Conditions: Myopia
Interventions: Control Lenses (comfilcon A with current process), Test Lenses (comfilcon A with novel process); Device
Lead sponsor: CooperVision International Limited (CVIL); Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Berkeley, California • Bloomington, Indiana • New York, New York + 2 more

Conditions: Tuberculosis
Interventions: MK-7762 (TBD09), Placebo; Drug · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 19 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Breast Cancer, Cardiac Toxicity
Interventions: Coreg CR®, lisinopril, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 174
States / cities: Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more

Search by objective public record fields.

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

An Emotion Regulation Intervention for Early Adolescent Risk Prevention

Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

Efficacy and Safety of Two Doses of HIL-214 in Children

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

Intracervical Lidocaine Gel for IUD Insertional Pain

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Telephone Tinnitus Education for Patients With Traumatic Brain Injury (TBI)

Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

Colchicine for the Treatment of Osteoarthritis of the Knee

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Effectiveness of CRD-740 in Heart Failure

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Clinical Evaluation of Reusable Soft Contact Lenses

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab